AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Executive Summary
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
You may also be interested in...
AbbVie Data Show Skyrizi Tops IL-17 Competitors In Skin Clearance
Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.
AbbVie’s Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs
The expansion of upadacitinib for a new indication in psoriatic arthritis has been pushed out three months to late in the second quarter.
AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.